Department of Nephrology, People's Hospital of Yichun City, Yichun, China.
Eur Rev Med Pharmacol Sci. 2020 May;24(9):4729-4737. doi: 10.26355/eurrev_202005_21161.
To investigate the function of HMGB2 in renal tumor ACHN cells in vitro and in vivo and to study the underlying molecular mechanisms.
Kaplan-Meier analysis was used to study the relationship between expression of HMGB2 and prognosis of renal tumor. MTT assay was employed to examine cell proliferation and flow cytometry analysis was used to study the role of HMGB2 in cell apoptosis in ACHN cells. Transwell assays were used to explore the migration and invasion of ACHN cells. The effect of HMGB2 on tumor growth was investigated in vivo. Western blot was performed to evaluate the expression levels of p-JNK, p-ERK and p-p38MAPK.
HMGB2 was upregulated in renal tumor and correlated with worse overall survival in renal tumor patients. Down-regulation of HMGB2 suppressed ACHN cells proliferation, invasion and migration in vitro. Moreover, down-regulation of HMGB2 inhibited tumor growth in vivo and HMGB2 exerts the oncogene function partly via the inhibition of p-p38MAPK activation.
Our results provide novel insights into neuropathic pain and help to explore therapeutic targets in the treatment.
研究 HMGB2 在体外和体内肾肿瘤 ACHN 细胞中的作用,并探讨其潜在的分子机制。
采用 Kaplan-Meier 分析研究 HMGB2 表达与肾肿瘤预后的关系。MTT 法检测细胞增殖,流式细胞术分析 HMGB2 对 ACHN 细胞凋亡的作用。Transwell 检测 ACHN 细胞的迁移和侵袭。体内研究 HMGB2 对肿瘤生长的影响。Western blot 检测 p-JNK、p-ERK 和 p-p38MAPK 的表达水平。
HMGB2 在肾肿瘤中上调,并与肾肿瘤患者的总生存期不良相关。下调 HMGB2 抑制 ACHN 细胞的体外增殖、侵袭和迁移。此外,下调 HMGB2 抑制体内肿瘤生长,HMGB2 通过抑制 p-p38MAPK 激活发挥致癌基因功能。
我们的研究结果为神经病理性疼痛提供了新的见解,并有助于探索治疗的治疗靶点。